Amarin Corp. PLC (NASDAQ:AMRN) shares traded up 1.8% during trading on Wednesday . The company traded as high as $2.30 and last traded at $2.26, with a volume of 599,994 shares trading hands. The stock had previously closed at $2.22.

A number of research analysts recently commented on the company. Jefferies Group restated a “buy” rating and issued a $3.50 target price on shares of Amarin Corp. PLC in a research note on Thursday, July 7th. Zacks Investment Research upgraded Amarin Corp. PLC from a “sell” rating to a “hold” rating in a research note on Wednesday, July 6th. Finally, HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Amarin Corp. PLC in a research note on Monday, May 9th.

The company’s market capitalization is $413.15 million. The stock has a 50-day moving average of $2.11 and a 200-day moving average of $1.72.

Amarin Corp. PLC (NASDAQ:AMRN) last posted its quarterly earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.11) by $0.03. The business earned $25.30 million during the quarter, compared to analysts’ expectations of $26.77 million. The firm’s revenue was up 60.4% on a year-over-year basis. During the same quarter last year, the business earned ($0.16) earnings per share. Equities research analysts anticipate that Amarin Corp. PLC will post ($0.49) EPS for the current fiscal year.

Several hedge funds and institutional investors have modified their holdings of AMRN. OppenheimerFunds Inc. increased its position in shares of Amarin Corp. PLC by 0.5% in the fourth quarter. OppenheimerFunds Inc. now owns 5,323,360 shares of the biopharmaceutical company’s stock valued at $10,061,000 after buying an additional 27,090 shares in the last quarter. Tamarack Advisers LP acquired a new position in shares of Amarin Corp. PLC during the fourth quarter valued at approximately $10,395,000. Finally, Oracle Investment Management Inc. increased its position in shares of Amarin Corp. PLC by 9.4% in the fourth quarter. Oracle Investment Management Inc. now owns 6,645,793 shares of the biopharmaceutical company’s stock valued at $12,561,000 after buying an additional 568,915 shares in the last quarter.

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.